VLA — Valneva SE Share News
0.000.00%
Last trade - 00:00- €440.83m
- €529.53m
- €174.66m
Brief: Valneva SE Says CDC Updates Recommendation For Valneva's Chikungunya Vaccine
US CDC advisers recommend lowering the age for RSV shots to 50-59 years (updated)
Brief: Valneva Receives First Marketing Authorization For Ixchiq® In Brazil
European healthcare drops as Trump says tariffs on sector coming soon
European healthcare drops as Trump says tariffs on sector coming soon
Brief: Valneva, LimmaTech Announce First Vaccination in Phase 2 Infant Study of Tetravalent Shigella Vaccine Candidate S4V2
French and Benelux stocks-Factors to watch
Brief: Valneva's Chikungunya Vaccine Authorized In EU For Adolescents Aged 12 And Above
Brief: Valneva Submits Adolescent Label Extension Application For Chikungunya Vaccine IXCHIQ® To UK MHRA
Brief: Valneva SE Files For Mixed Shelf Of Up To $350 Million
Valneva jumps after deal to provide chikungunya vaccine
Brief: Valneva Responds To Chikungunya Outbreak In La Réunion With Vaccine
Valneva edges up on 'well oriented' FY, 'solid' forecasts
French and Benelux stocks-Factors to watch
Brief: Valneva Expects 2025 Sales To Grow To EUR 170-180 Mln
French and Benelux stocks-Factors to watch
Brief: Valneva Receives EMA’s Positive CHMP Opinion for Adolescent Label Extension for Chikungunya Vaccine IXCHIQ
Brief: EMA's CHMP Says Opinion Recommending Marketing Authorisation For Leqembi Not Need To Be Updated
Refile: BUZZ-Valneva rises on positive surprise from 2025 topline, cash burn outlook